{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:34:49Z","timestamp":1771461289161,"version":"3.50.1"},"reference-count":92,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Immune checkpoint inhibitors have been investigated in acute myeloid leukemia (AML) with an intent to harness the immune microenvironment components to generate an immune response against leukemia. Anti\u2013cytotoxic T-lymphocyte\u2013associated antigen 4 and anti\u2013programmed cell death 1\/programmed cell death ligand 1 antibodies have been evaluated in combination with low-intensity therapy and cytotoxic chemotherapy, both in the pretransplant and posttransplant settings. Although the objective response rates with programmed cell death 1\u2013 and programmed cell death ligand 1\u2013based therapies have been relatively low, durable stable disease and hematologic improvement were noted in a subset of patients, important endpoints in patients with limited therapeutic options. Novel AML and myelodysplastic syndrome\u2013specific checkpoints such as TIM3 antibodies in combination with azacitidine are showing encouraging efficacy, especially durability of response, in ongoing studies. Anti-CD47\/SIRP\u03b1 therapy in combination with azacitidine has shown encouraging efficacy and safety in frontline AML, especially in TP53-mutated AML, a population of significant unmet need. Other T cell\u2013based immune therapies are under investigation. T-cell and natural killer cell bispecific and trispecific engagers have shown modest activity in patients with relapsed and\/or refractory AML albeit with frequent cytokine release syndrome. Chimeric antigen receptor T-cell therapy showed immense success in many lymphoid malignancies and is being evaluated in AML. Future trials should be designed to select patients based on markers of response and tailor therapies according to predictive biomarkers.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000573","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T19:10:41Z","timestamp":1642792241000},"page":"43-50","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Checkpoint Inhibitors and Other Immune-Based Therapies in Acute Myeloid Leukemia"],"prefix":"10.1097","volume":"28","author":[{"given":"Fadi","family":"Haddad","sequence":"first","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Medical Oncology, Department of Medicine, Yale University School of Medicine, New Haven, CT."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naval","family":"Daver","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"16 suppl","key":"bib1-20250621","first-page":"S347","article-title":"Unmet clinical needs and economic burden of disease in the treatment landscape of acute myeloid leukemia","volume":"24","year":"2018","journal-title":"Am J Manag Care"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11095-019-2654-z","article-title":"Recent treatment advances and the role of nanotechnology, combination products, and immunotherapy in changing the therapeutic landscape of acute myeloid leukemia","volume":"36","year":"2019","journal-title":"Pharm Res"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.critrevonc.2016.12.004","article-title":"Frontline treatment of acute myeloid leukemia in adults","volume":"110","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cncr.22779","article-title":"Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes","volume":"110","year":"2007","journal-title":"Cancer"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"634435","DOI":"10.3389\/fimmu.2021.634435","article-title":"The role of immune checkpoint molecules for relapse after allogeneic hematopoietic cell transplantation","volume":"12","year":"2021","journal-title":"Front Immunol"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1056\/NEJMoa1601202","article-title":"Ipilimumab for patients with relapse after allogeneic transplantation","volume":"375","year":"2016","journal-title":"N Engl J Med"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1182\/blood.2019004710","article-title":"A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation","volume":"135","year":"2020","journal-title":"Blood"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/s41375-018-0070-8","article-title":"Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes","volume":"32","year":"2018","journal-title":"Leukemia"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"12840","DOI":"10.18632\/oncotarget.7326","article-title":"Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy","volume":"7","year":"2016","journal-title":"Oncotarget"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"7050","DOI":"10.1158\/0008-5472.CAN-06-0004","article-title":"Disruption of EphA2 receptor tyrosine kinase leads to increased susceptibility to carcinogenesis in mouse skin","volume":"66","year":"2006","journal-title":"Cancer Res"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.18632\/oncotarget.1542","article-title":"Alterations of immune response of non-small cell lung cancer with azacytidine","volume":"4","year":"2013","journal-title":"Oncotarget"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/leu.2013.355","article-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents","volume":"28","year":"2014","journal-title":"Leukemia"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","article-title":"Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study","volume":"9","year":"2019","journal-title":"Cancer Discov"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1182\/bloodadvances.2021004583","article-title":"Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti\u2013PD-1\u2013based therapy","volume":"5","year":"2021","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"bib17-20250621","first-page":"832","article-title":"Multi-center phase 2 study of pembroluzimab (Pembro) and azacitidine (AZA) in patients with relapsed\/refractory acute myeloid leukemia (AML) and in newly diagnosed (\u226565 years) AML patients","volume":"134","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"bib18-20250621","first-page":"1437","article-title":"Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia","volume":"132","year":"2018","journal-title":"Blood"},{"key":"bib19-20250621","first-page":"43","article-title":"Azacitidine (AZA) with nivolumab (nivo), and AZA with nivo + ipilimumab (Ipi) in relapsed\/refractory (R\/R) acute myeloid leukemia: clinical and immune biomarkers of response","volume":"136","year":"2020","journal-title":"Blood"},{"key":"bib20-20250621","article-title":"Azacitidine and Durvalumab in First-line Treatment of Elderly Patients With Acute Myeloid Leukemia","year":"2021","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"bib21-20250621","first-page":"1428","article-title":"Single-cell mass cytometry identifies mechanisms of resistance to immunotherapy in AML","volume":"134","year":"2019","journal-title":"Blood"},{"key":"bib22-20250621","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1080\/10428194.2017.1344905","article-title":"The emerging role of immune checkpoint based approaches in AML and MDS","volume":"59","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"bib23-20250621","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"bib24-20250621","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.immuni.2013.06.014","article-title":"Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance","volume":"39","year":"2013","journal-title":"Immunity"},{"key":"bib25-20250621","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrclinonc.2010.223","article-title":"Immune parameters affecting the efficacy of chemotherapeutic regimens","volume":"8","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"bib26-20250621","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3626","article-title":"The secret ally: immunostimulation by anticancer drugs","volume":"11","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"bib27-20250621","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/0008-5472.CAN-03-3259","article-title":"PD-L1\/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells","volume":"64","year":"2004","journal-title":"Cancer Res"},{"key":"bib28-20250621","doi-asserted-by":"crossref","first-page":"6580","DOI":"10.1158\/1078-0432.CCR-12-1362","article-title":"Molecular pathways: next-generation immunotherapy\u2014inhibiting programmed death-ligand 1 and programmed death-1","volume":"18","year":"2012","journal-title":"Clin Cancer Res"},{"key":"bib29-20250621","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.1016\/S2352-3026(19)30114-0","article-title":"Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study","volume":"6","year":"2019","journal-title":"Lancet Haematol"},{"key":"bib30-20250621","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1158\/2643-3230.BCD-21-0070","article-title":"Phase II trial of pembrolizumab after high-dose cytarabine in relapsed\/refractory acute myeloid leukemia [published September 10, 2021]","volume":"2","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"bib31-20250621","doi-asserted-by":"crossref","first-page":"eaaz0463","DOI":"10.1126\/scitranslmed.aaz0463","article-title":"Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia","volume":"12","year":"2020","journal-title":"Sci Transl Med"},{"key":"bib32-20250621","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.2020007732","article-title":"Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia","volume":"137","year":"2021","journal-title":"Blood"},{"key":"bib33-20250621","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/cncr.32796","article-title":"Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML\/MDS who are treated with checkpoint inhibitors","volume":"126","year":"2020","journal-title":"Cancer"},{"key":"bib34-20250621","doi-asserted-by":"crossref","first-page":"e001818","DOI":"10.1136\/jitc-2020-001818","article-title":"Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia\/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation","volume":"9","year":"2021","journal-title":"J Immunother Cancer"},{"key":"bib35-20250621","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0962-8924(00)01906-1","article-title":"Integrin-associated protein (CD47) and its ligands","volume":"11","year":"2001","journal-title":"Trends Cell Biol"},{"key":"bib36-20250621","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nri1859","article-title":"The SIRP family of receptors and immune regulation","volume":"6","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"bib37-20250621","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.4049\/jimmunol.174.4.2004","article-title":"Negative regulation of phagocytosis in macrophages by the CD47-SHPS-1 system","volume":"174","year":"2005","journal-title":"J Immunol"},{"key":"bib38-20250621","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells","volume":"138","year":"2009","journal-title":"Cell"},{"key":"bib39-20250621","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","article-title":"CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis","volume":"138","year":"2009","journal-title":"Cell"},{"key":"bib40-20250621","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1158\/0008-5472.CAN-10-2238","article-title":"Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia","volume":"71","year":"2011","journal-title":"Cancer Res"},{"key":"bib41-20250621","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1038\/sj.cdd.4402201","article-title":"Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light\u2013induced apoptosis","volume":"14","year":"2007","journal-title":"Cell Death Differ"},{"issue":"suppl 1","key":"bib42-20250621","first-page":"2729","article-title":"Combination treatment with 5F9 and azacitidine enhances phagocytic elimination of acute myeloid leukemia","volume":"132","year":"2018","journal-title":"Blood"},{"key":"bib43-20250621","doi-asserted-by":"crossref","first-page":"67","DOI":"10.36401\/JIPO-21-X2","article-title":"Targeting CD47\/SIRP\u03b1 in acute myeloid leukemia and myelodysplastic syndrome: preclinical and clinical developments of magrolimab","volume":"4","year":"2021","journal-title":"J Immunother Precis Oncol"},{"key":"bib44-20250621","doi-asserted-by":"crossref","first-page":"S290","DOI":"10.1016\/S2152-2650(21)01694-3","article-title":"AML-196: the first-in-class anti-CD47 antibody magrolimab in combination with azacitidine is well tolerated and effective in AML patients: phase 1b results","volume":"21","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl 1","key":"bib45-20250621","first-page":"30","article-title":"A phase I\/IIa study of lemzoparlimab, a monoclonal antibody targeting CD47, in patients with relapsed and\/or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): initial phase I results","volume":"136","year":"2020","journal-title":"Blood"},{"key":"bib46-20250621","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1158\/1078-0432.CCR-16-1700","article-title":"TTI-621 (SIRP\u03b1Fc): a CD47-blocking innate immune checkpoint inhibitor with broad antitumor activity and minimal erythrocyte binding","volume":"23","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"suppl 1","key":"bib47-20250621","first-page":"19","article-title":"DSP107, a novel bi-functional fusion protein that combines inhibition of CD47 with targeted activation of 4-1BB to trigger innate and adaptive anticancer immune responses","volume":"136","year":"2020","journal-title":"Blood"},{"key":"bib48-20250621","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.stem.2010.11.014","article-title":"TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells","volume":"7","year":"2010","journal-title":"Cell Stem Cell"},{"key":"bib50-20250621","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/sj.leu.2402890","article-title":"Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19\/anti-CD3 single-chain antibody construct","volume":"17","year":"2003","journal-title":"Leukemia"},{"key":"bib51-20250621","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/0008-5472.CAN-09-0547","article-title":"Bispecific T-cell engaging antibodies for cancer therapy","volume":"69","year":"2009","journal-title":"Cancer Res"},{"key":"bib52-20250621","first-page":"149","article-title":"Tumor and T cell engagement by BiTE","volume":"16","year":"2013","journal-title":"Discov Med"},{"key":"bib53-20250621","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","year":"2017","journal-title":"N Engl J Med"},{"key":"bib54-20250621","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1365-2362.2007.01746.x","article-title":"Expression of the target receptor CD33 in CD34+\/CD38\u2212\/CD123+ AML stem cells","volume":"37","year":"2007","journal-title":"Eur J Clin Invest"},{"key":"bib55-20250621","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1182\/blood.V67.4.1048.1048","article-title":"Expression of normal myeloid-associated antigens by acute leukemia cells","volume":"67","year":"1986","journal-title":"Blood"},{"key":"bib56-20250621","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1182\/blood-2013-09-527044","article-title":"Cellular determinants for preclinical activity of a novel CD33\/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML","volume":"123","year":"2014","journal-title":"Blood"},{"key":"bib57-20250621","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1158\/1535-7163.MCT-13-0956","article-title":"Preclinical characterization of AMG 330, a CD3\/CD33-bispecific T-cell\u2013engaging antibody with potential for treatment of acute myelogenous leukemia","volume":"13","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"15_suppl","key":"bib58-20250621","doi-asserted-by":"crossref","first-page":"7508","DOI":"10.1200\/JCO.2020.38.15_suppl.7508","article-title":"Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed\/refractory acute myeloid leukemia (R\/R AML)","volume":"38","year":"2020","journal-title":"JCO"},{"key":"bib59-20250621","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1182\/blood-2013-08-523548","article-title":"CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330","volume":"123","year":"2014","journal-title":"Blood"},{"issue":"suppl 1","key":"bib60-20250621","first-page":"833","article-title":"Preliminary results from a phase 1 first-in-human study of AMG 673, a novel half-life extended (HLE) anti-CD33\/CD3 BiTE\u00ae (bispecific T-cell engager) in patients with relapsed\/refractory (R\/R) acute myeloid leukemia (AML)","volume":"134","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"bib61-20250621","first-page":"4","article-title":"Complete responses in relapsed\/refractory acute myeloid leukemia (AML) patients on a weekly dosing schedule of vibecotamab (XmAb14045), a CD123 x CD3 T Cell-engaging bispecific antibody; initial results of a phase 1 study","volume":"136","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"bib62-20250621","first-page":"11","article-title":"Preliminary results from a phase 1 study of APVO436, a novel anti-CD123 x Anti-CD3 Bispecific Molecule, in Relapsed\/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome","volume":"136","year":"2020","journal-title":"Blood"},{"key":"bib63-20250621","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1182\/blood-2007-03-083048","article-title":"The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells","volume":"110","year":"2007","journal-title":"Blood"},{"key":"bib64-20250621","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/s41375-020-01065-5","article-title":"A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells","volume":"35","year":"2021","journal-title":"Leukemia"},{"issue":"suppl 1","key":"bib65-20250621","first-page":"7","article-title":"GTB-3550 TriKE\u2122 for the treatment of high-risk myelodysplastic syndromes (MDS) and refractory\/relapsed acute myeloid leukemia (AML) safely drives natural killer (NK) cell proliferation at initial dose cohorts","volume":"136","year":"2020","journal-title":"Blood"},{"key":"bib66-20250621","first-page":"e1472195","article-title":"Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells","volume":"7","year":"2018","journal-title":"Onco Targets Ther"},{"key":"bib67-20250621","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s11899-018-0472-8","article-title":"Bispecific antibodies for the treatment of acute myeloid leukemia","volume":"13","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"issue":"suppl 1","key":"bib68-20250621","first-page":"834","article-title":"Phase 1 first-in-human trial of AMV564, a bivalent bispecific (2:2) CD33\/CD3 T-cell engager, in patients with relapsed\/refractory acute myeloid leukemia (AML)","volume":"134","year":"2019","journal-title":"Blood"},{"key":"bib69-20250621","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.molimm.2011.09.019","article-title":"Unexpected recombinations in single chain bispecific anti-CD3\u2013anti-CD33 antibodies can be avoided by a novel linker module","volume":"49","year":"2011","journal-title":"Mol Immunol"},{"key":"bib70-20250621","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/leu.2013.18","article-title":"Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells","volume":"27","year":"2013","journal-title":"Leukemia"},{"key":"bib71-20250621","doi-asserted-by":"crossref","first-page":"381","DOI":"10.4161\/mabs.27385","article-title":"A new class of bispecific antibodies to redirect T cells for cancer immunotherapy","volume":"6","year":"2014","journal-title":"MAbs"},{"key":"bib72-20250621","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/blood-2014-05-575704","article-title":"Targeting CD123 in acute myeloid leukemia using a T-cell\u2013directed dual-affinity retargeting platform","volume":"127","year":"2016","journal-title":"Blood"},{"key":"bib73-20250621","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1182\/bloodadvances.2020002512","article-title":"TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML","volume":"4","year":"2020","journal-title":"Blood Adv"},{"key":"bib74-20250621","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","year":"2015","journal-title":"Science"},{"key":"bib75-20250621","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1084\/jem.181.5.1653","article-title":"Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes","volume":"181","year":"1995","journal-title":"J Exp Med"},{"key":"bib76-20250621","first-page":"303ra139","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","year":"2015","journal-title":"Sci Transl Med"},{"key":"bib77-20250621","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/asheducation.V2012.1.143.3798224","article-title":"Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen","volume":"2012","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"bib78-20250621","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/(SICI)1097-0215(19970926)73:1<50::AID-IJC9>3.0.CO;2-0","article-title":"Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group\u2013related antigens","volume":"73","year":"1997","journal-title":"Int J Cancer"},{"key":"bib79-20250621","first-page":"1553","article-title":"Expression of Lewisa, Lewisb, X, and Y blood group antigens in human colonic tumors and normal tissue and in human tumor-derived cell lines","volume":"46","year":"1986","journal-title":"Cancer Res"},{"key":"bib80-20250621","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/mt.2013.154","article-title":"Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia","volume":"21","year":"2013","journal-title":"Mol Ther"},{"issue":"suppl 1","key":"bib81-20250621","first-page":"811","article-title":"Remissions of acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm following treatment with CD123-specific CAR T cells: a first-in-human clinical trial","volume":"130","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"bib82-20250621","first-page":"902","article-title":"Remissions in relapse\/refractory acute myeloid leukemia patients following treatment with NKG2D CAR-T therapy without a prior preconditioning chemotherapy","volume":"132","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"bib84-20250621","first-page":"901","article-title":"First-in-human CLL1-CD33 compound CAR T cell therapy induces complete remission in patients with refractory acute myeloid leukemia: update on phase 1 clinical trial","volume":"132","year":"2018","journal-title":"Blood"},{"key":"bib85-20250621","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrclinonc.2017.128","article-title":"Chimeric antigen receptor T-cell therapies for lymphoma","volume":"15","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"bib86-20250621","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1182\/blood-2016-02-629063","article-title":"CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date","volume":"127","year":"2016","journal-title":"Blood"},{"key":"bib87-20250621","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1053\/j.seminhematol.2018.08.008","article-title":"Will CAR T cell therapy have a role in AML? Promises and pitfalls","volume":"56","year":"2019","journal-title":"Semin Hematol"},{"key":"bib88-20250621","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1038\/s41375-021-01253-x","article-title":"T-cell\u2013based immunotherapy of acute myeloid leukemia: current concepts and future developments","volume":"35","year":"2021","journal-title":"Leukemia"},{"key":"bib89-20250621","doi-asserted-by":"crossref","first-page":"10437","DOI":"10.1073\/pnas.95.18.10437","article-title":"Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity","volume":"95","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"bib90-20250621","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1182\/blood-2004-11-4564","article-title":"An inducible caspase 9 safety switch for T-cell therapy","volume":"105","year":"2005","journal-title":"Blood"},{"key":"bib91-20250621","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s13238-017-0411-9","article-title":"Increasing the safety and efficacy of chimeric antigen receptor T cell therapy","volume":"8","year":"2017","journal-title":"Protein Cell"},{"key":"bib92-20250621","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","article-title":"Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia","volume":"173","year":"2018","journal-title":"Cell"},{"key":"bib93-20250621","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood.2019002779","article-title":"Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia","volume":"135","year":"2020","journal-title":"Blood"},{"key":"bib94-20250621","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/17474086.2018.1459184","article-title":"Checkpoint inhibitors and acute myelogenous leukemia: promises and challenges","volume":"11","year":"2018","journal-title":"Expert Rev Hematol"},{"key":"bib95-20250621","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition [published online December 20, 2017]","volume":"377","year":"2017","journal-title":"N Engl J Med"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000573","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T17:00:28Z","timestamp":1750525228000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":92,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000573","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}